Gregory Caillet

Gregory Caillet currently serves as Medical Director at Almirall, where he plays a pivotal role in advancing the company's dermatology portfolio, with a particular focus on innovative therapies for inflammatory skin conditions such as psoriasis. In this capacity, Gregory leverages his extensive expertise in clinical research, medical affairs, and dermatology to support the strategic launch and positioning of novel treatments like Tildrakizumab, an anti-IL23 biologic. His responsibilities encompass the development and execution of expert engagement plans tailored to key opinion leaders (KOLs) and healthcare professionals across France, ensuring that scientific communication aligns with regulatory standards and clinical needs.

Throughout his tenure at Almirall, Gregory has been instrumental in orchestrating key projects related to the launch of Tildrakizumab for plaques psoriasis, overseeing medical activities that include medical training, scientific dissemination, and stakeholder engagement. His deep understanding of clinical trial design, real-world evidence (RWE) generation, and data quality management has been crucial in supporting the evidence-based positioning of new therapies. Gregory’s background in clinical research, combined with his skills in CRO management and biotechnologies, enables him to navigate complex clinical development processes effectively.

Prior to his current role, Gregory contributed as a medical affairs manager in dermatology, supporting RWE studies with Apremilast and other dermatological agents, emphasizing his commitment to advancing personalized treatment options through robust clinical data. His expertise spans a broad spectrum of therapeutic areas, including inflammation, neurology, cardiology, and biopharmaceuticals, making him a versatile leader in the pharmaceutical industry. Gregory Caillet’s strategic vision and scientific rigor continue to drive Almirall’s mission to improve patient outcomes through innovative dermatological solutions.